Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献76篇:

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M1nxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2XFczKGh? MWfEUXNQ M2fuR2lEPTB;MD6wNFAxPyEQvF2= NH7q[GkyPzl3NkC4NC=>
K562 NEfyUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG3NkBp MVzEUXNQ MnLwTWM2OD1yLkCwNUDPxE1? NVfoWIN[OTd7NU[wPFA>
M07e M13Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j4eFczKGh? MY\EUXNQ Ml;zTWM2OD1yLkCwNVIh|ryP NHroUFUyPzl3NkC4NC=>
ALL3 NYDYOWh2S3m2b4TvfIlkKEG|c3H5 MkfONE4y|ryP MUi3NkBp MULEUXNQ NET0PWtKSzVyPUCuNFAxPCEQvF2= NFjzS|EyQTh6OUW0NC=>
CML M1TW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOyNEBucW5? M3THNWROW09? Mnj0TWM2OD1yLkCwNUDPxE1? NGToUZIyQTJzOUCxOi=>
BA/F3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXte3ZTPzJiaB?= MkTnSG1UVw>? NUjZWJFDUUN3ME22MlU5QSEQvF2= NVXY[ItHOjNyOEi2OFQ>
BA/F3 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXPTZc4OiCq MWPEUXNQ NVfJSlBIUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> MVSyN|A5QDZ2NB?=
BA/F3 M{Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp M4fk[GROW09? NE\kPWlKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MU[yN|A5QDZ2NB?=
BA/F3 M1fGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOxO|IhcA>? MVTEUXNQ NEjrNFFKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= MXqyN|A5QDZ2NB?=
BA/F3 NWX0epc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHzPZp5PzJiaB?= NF;XS5dFVVOR NX\PdGw{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= NGLCNGozOzNyMUewNy=>
BA/F3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxe3M4OiCq NWrMc|lSTE2VTx?= MYrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? MYOyN|MxOTdyMx?=
BA/F3 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpdZQ4OiCq NITjbVlFVVOR NHH4UmRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MnW2NlM{ODF5MEO=
BA/F3 NWm0d3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu3NkBp NELER5pFVVOR M{P5VGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1? MWiyN|MxOTdyMx?=
BA/F3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T3c|czKGh? NE\YVW9FVVOR NFLYUJdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MkizNlM{ODF5MEO=
BA/F3 M1Tv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPRXdEPzJiaB?= M4rkWmROW09? MlPMTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> NWfXbZA3OjN|MEG3NFM>
BA/F3 M3G3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6weoE4OiCq MoHFSG1UVw>? MmPQTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? MV2yN|MxOTdyMx?=
BA/F3 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrr[m44OiCq NIm0TYNFVVOR NHHKNVBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? MXiyN|MxOTdyMx?=
BA/F3 NG\UdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW3O|IhcA>? MnO4SG1UVw>? MkjMTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP MV:yN|MxOTdyMx?=
T cell MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPqTYFFPzJiaB?= M1H5b2ROW09? NU\kNHhrUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? M{TCT|E4OTV2NUGy
WiDr M13TOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37OSVczKGh? M132WmROW09? M4PkZmlEPTB;MD6wOVIh|ryP MkL5NVU3OTV3MUK=
PC3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzHWnpWPzJiaB?= NGDCZnZFVVOR NYSw[pZQUUN3ME2wMlAxQTRizszN NITTbGgyPTZzNUWxNi=>
MDA-MB-231 NX;JRVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG3NkBp MWDEUXNQ NFvmXo9KSzVyPUCuNFEzKM7:TR?= M3fwUFE2PjF3NUGy
Hs578T MnrDR5l1d3SxeHnjJGF{e2G7 NXO4Z3JXPzJiaB?= NYLrOJRvTE2VTx?= NH;PU2RIUTVyPUCuNFMh|ryP M2[yZ|I1ODF3M{K3
HMEC MXnDfZRwfG:6aXOgRZN{[Xl? M4XI[FczKGh? M3PRO2ROW09? Ml;YS2k2OD1zLkig{txO NHrY[20zPDBzNUOyOy=>
DU145 M2PlZmN6fG:2b4jpZ{BCe3OjeR?= NYrGZ|BJPzJiaB?= NGnRXW9FVVOR NFn4bHNIUTVyPUCuNVYh|ryP M{LPWFI1ODF3M{K3
U251 Mn\OR5l1d3SxeHnjJGF{e2G7 NV74eo5TPzJiaB?= NUK4eo1QTE2VTx?= MmfQS2k2OD1{LkixJO69VQ>? NFXnNnIzPDBzNUOyOy=>
NCI60 MYfDfZRwfG:6aXOgRZN{[Xl? MY[3NkBp MXrEUXNQ M3PLV2dKPTB;NT63JO69VQ>? MVqyOFAyPTN{Nx?=
MALME-3M MoTLR5l1d3SxeHnjJGF{e2G7 M2LwbVczKGh? MnKySG1UVw>? NFzGS|BIUTVyPU[uOlEh|ryP MmDaNlQxOTV|Mke=
KM12 NGDWSZJEgXSxdH;4bYMhSXO|YYm= NHvkZok4OiCq NFXLdXVFVVOR NVjz[3pQT0l3ME23MlQ1KM7:TR?= MmjJNlQxOTV|Mke=
SW620 Mn31R5l1d3SxeHnjJGF{e2G7 NHnqT2w4OiCq MnXMSG1UVw>? MWLHTVUxRThwNEOg{txO NIT1dGYzPDBzNUOyOy=>
RXF 393NL M16xUmN6fG:2b4jpZ{BCe3OjeR?= Mmq4OEBl[Xm| NG\lUIVFVVOR M2LkXWlEPTB;MD6wNlE4KM7:TR?= NVT1R|U1OjN{NUOwO|Q>
LXFA 983L MW\DfZRwfG:6aXOgRZN{[Xl? NWL3ZppnPCCmYYnz NF3KUVhFVVOR M1rVU2lEPTB;MD6wOVY2KM7:TR?= NX7NWXZXOjN{NUOwO|Q>
PRXF DU145 M{XkZmN6fG:2b4jpZ{BCe3OjeR?= MVq0JIRigXN? MWfEUXNQ MnHLTWM2OD1yLkC2NlMh|ryP NHjKWJYzOzJ3M{C3OC=>
PAXF 1657L MnHMR5l1d3SxeHnjJGF{e2G7 M17Ee|Qh\GG7cx?= NGr4W4RFVVOR MYrJR|UxRTBwMUKxJO69VQ>? M1fkfFI{OjV|MEe0
CXF 1103L NYC2OoFoS3m2b4TvfIlkKEG|c3H5 M4LBe|Qh\GG7cx?= MkjrSG1UVw>? NUftPHRUUUN3ME20MlM3KM7:TR?= MVWyN|I2OzB5NB?=
GXF251L M3HhNGN6fG:2b4jpZ{BCe3OjeR?= MlXEOEBl[Xm| MYDEUXNQ M1:wUmlEPTB;Mj6yOUDPxE1? NHnQSJMzOzJ3M{C3OC=>
NCI-H23 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPzUFRYPzJiaB?= MW\EUXNQ M3rIPWlEPTB;Mj6yO{DPxE1? NGnnbpkzOzV{MUCyNC=>
HCT116 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfFOpNsPzJiaB?= NEP3SoJFVVOR NH;2[lBKSzVyPUKuN{DPxE1? MmTmNlM2OjFyMkC=
MCF7 M{\UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ib3A4OiCq M2\WO2ROW09? Mlz0TWM2OD1{LkW3JO69VQ>? MoDQNlM2OjFyMkC=
NCI-H460 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp MknNSG1UVw>? M4W4[2lEPTB;OD65PUDPxE1? MlKyNlM2OjFyMkC=
DLD1 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\VVHRoPzJiaB?= M{i5c2ROW09? M3y5SWlEPTB;ND62JO69VQ>? NHvYN4EzOzV4N{m2NC=>
NCI-H661 NYPDWW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi3NkBp M2jOUWROW09? MlfWTWM2OD15Lkig{txO NU[1NoJlOjN3Nke5OlA>
A549 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj0cWY4OiCq NXWxbo5sTE2VTx?= NXznTIRRUUN3ME24MlIh|ryP M{H0S|I{PTZ5OU[w
U937 NY\Id4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LWc|czKGh? NEn2bIVFVVOR NGHmO4hKSzVyPUGyMlIh|ryP MWeyN|U3Pzl4MB?=
HEK293 M2LFNWZ2dmO2aX;uJGF{e2G7 NIHnfHoyOMLizszN M3nnbmROW09? NGHyUXFKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> NFjDbZgzOjd5ME[xNC=>
HUVEC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1NE4yPcLizszN MWK3NkBp NHrabJRFVVOR NIG3XIVKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> M2HyNlIzQDV|OUmz
HUVEC NWf1OnhNTnWwY4Tpc44hSXO|YYm= M3vEU|E2yqEQvF2= NFLuO5o4OiCq MWnEUXNQ Ml7GTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0> MnnGNlI5PTN7OUO=
Plasmodium falciparum MmTWSpVv[3Srb36gRZN{[Xl? MkHRNVDDqM7:TR?= NHjuO3EyPSCvaX6= MV7EUXNQ NXTsWIhUUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NHTBWW8zPDV3MEOzNC=>
PC3 NYLBUXN7TnWwY4Tpc44hSXO|YYm= M3LlOVAvOSEQvF2= MXS1JIg> NUTzWmNuTE2VTx?= M4DkVGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MnjrNVk1PjJ7N{W=
DU145 MkG3SpVv[3Srb36gRZN{[Xl? NX3ZT5QzOC5zIN88US=> M4fnRlUhcA>? NXjVenp7TE2VTx?= MnfXTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= Ml24NVk1PjJ7N{W=
PC3 NUPYTHZLU2mwYYPlJGF{e2G7 NEj5NmkxNjFizszN M4LL[|UhcA>? M4flbGROW09? MmnyTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= M1vLXFE6PDZ{OUe1
DU145 MYjLbY5ie2ViQYPzZZk> NFv2ZXYxNjFizszN M2TKZ|UhcA>? NI\2[2JFVVOR NUfRVo1[UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O M4rsS|E6PDZ{OUe1
PC3 NVf0PHRHU2mwYYPlJGF{e2G7 M{PpRVAvOSEQvF2= Mk\1OUBp M1nIS2ROW09? NEHRbHRKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NWTB[nR2OTl2NkK5O|U>
DU145 NWHWOpRyU2mwYYPlJGF{e2G7 MWewMlEh|ryP NGG5Z4k2KGh? MWXEUXNQ NGfX[VdKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NYLQdXRpOTl2NkK5O|U>
Huh7 NUTaOXhZSW62aY\pdoFtKEG|c3H5 MUKyMlUh|ryP NXrpbZRWPCCmYYnz NF;HWopFVVOR MkXDTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MVKxO|M3ODZ5Nh?=
C6/36 M{fhRWFvfGm4aYLhcEBCe3OjeR?= NEDnU5kzNjVizszN NITQTWQ1KGSjeYO= NUPPS49XTE2VTx?= MYnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO MXqxO|M3ODZ5Nh?=
U937 NGTDZWRHfW6ldHnvckBCe3OjeR?= NHTZW|YyKM7:TR?= NH3hXWwyKGh? M1XzU2ROW09? NVvIVIhDWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NV71elV3OTd4OESwPVk>
U937 NV3VUGhwTnWwY4Tpc44hSXO|YYm= M3nRflEh|ryP M3T6O|EhcA>? NIfJWpdFVVOR MnPyVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> NUH5e2Z2OTd4OESwPVk>
murine mast cell NHO3dIZHfW6ldHnvckBCe3OjeR?= NX7hVHQzOSEQvF2= MYGyOEBp M4DjeWROW09? M2f2eGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP M{LzR|E4Pjh2MEm5
BV-173 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r6dWlEPTB;MD6wNFAxODBzMEmg{txO M4H6N3NCVkeHUh?=
K-562 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMECwNFAxOjZ4IN88US=> MkHUV2FPT0WU
BL-70 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3lbphKSzVyPUCuNFAxODByOEKyJO69VQ>? MVzTRW5ITVJ?
EM-2 NEjDWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXHOJNKSzVyPUCuNFAxODBzMEig{txO NWfuNYtiW0GQR1XS
LAMA-84 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rNZ2lEPTB;MD6wNFAxODN{MTFOwG0> NVfvO|BJW0GQR1XS
MEG-01 M3G1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMECwNFA6QCEQvF2= NH30XW5USU6JRWK=
EoL-1-cell NFXh[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXBTWM2OD1yLkCwNFAyOzFizszN MXzTRW5ITVJ?
CTV-1 NWfYeIdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnDfHZzUUN3ME2wMlAxODB2MESg{txO NGHVNnNUSU6JRWK=
TE-15 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnZbHRJUUN3ME2wMlAxPTh7IN88US=> NH\FVmtUSU6JRWK=
NOS-1 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\MeWlEPTB;MD6wNFYyOyEQvF2= MlnoV2FPT0WU
D-336MG NY\4WGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v6N2lEPTB;MD6wNFY{KM7:TR?= NWS5OFBEW0GQR1XS
LB1047-RCC NYXjSlM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzVelJKSzVyPUCuNFA6QDlizszN MUXTRW5ITVJ?
LB996-RCC M2Tyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnuVo5KSzVyPUCuNFA6QTFizszN MnfXV2FPT0WU
SW982 M33FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjFV|BKSzVyPUCuNFEyOTVizszN NYmwWpNPW0GQR1XS
TK10 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4enRmUUN3ME2wMlAyOTd2IN88US=> NEHYT4dUSU6JRWK=
A704 NXTLUms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEG0PVEh|ryP NEn1WHlUSU6JRWK=
TE-8 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:3TWM2OD1yLkCxOVc3KM7:TR?= M1;ZWnNCVkeHUh?=
DOHH-2 M2fzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEG3NVkh|ryP MYjTRW5ITVJ?
HOP-62 M33I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1VGhKSzVyPUCuNFE5OzRizszN NUTzZ4MzW0GQR1XS
TE-12 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEG4OlEh|ryP NF35fIZUSU6JRWK=
KGN NVHCSZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLRTWM2OD1yLkCxPVQzKM7:TR?= NE\HN5NUSU6JRWK=
NCI-H1648 M{[4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEKwNVEh|ryP MX;TRW5ITVJ?
OS-RC-2 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TTR2lEPTB;MD6wNlA{KM7:TR?= M2qycHNCVkeHUh?=
GB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jPNmlEPTB;MD6wNlE2PyEQvF2= MX;TRW5ITVJ?
RXF393 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwTWM2OD1yLkCyN|U4KM7:TR?= MWjTRW5ITVJ?
LC-2-ad NHjEVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nmZmlEPTB;MD6wNlU5PiEQvF2= NFnFdIdUSU6JRWK=
KS-1 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEK3N{DPxE1? MXLTRW5ITVJ?
ETK-1 M{mxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD1yLkCyPFMzKM7:TR?= MWTTRW5ITVJ?
SW954 NYnuVFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e2XmlEPTB;MD6wNlkzPyEQvF2= NX\RT45EW0GQR1XS
Becker M4PrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDhTWM2OD1yLkCzNFA{KM7:TR?= NYPzRYN7W0GQR1XS
MZ1-PC M1y3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMEOxNVkh|ryP NGLic3NUSU6JRWK=
ES6 NVyzcm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEOxPVMh|ryP NIDF[4VUSU6JRWK=
KURAMOCHI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEO0PFch|ryP MWfTRW5ITVJ?
CGTH-W-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vDOGlEPTB;MD6wN|U1QCEQvF2= MV\TRW5ITVJ?
VA-ES-BJ MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHOTWM2OD1yLkCzPVAzKM7:TR?= NVTGSnlCW0GQR1XS
LXF-289 NWPne|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3KfIFLUUN3ME2wMlA{QTV4IN88US=> M1yzPHNCVkeHUh?=
MPP-89 NVjaNJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfBW3pvUUN3ME2wMlA1ODR7IN88US=> NWXze|ZXW0GQR1XS
SW872 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTMTJpJUUN3ME2wMlA1OTZzIN88US=> NF7xcWdUSU6JRWK=
SNB75 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHVOJJKSzVyPUCuNFQ1OzVizszN M2r5N3NCVkeHUh?=
PSN1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPSTWM2OD1yLkC0OFc1KM7:TR?= M4XJR3NCVkeHUh?=
LB831-BLC NYjoSopGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBOGlEPTB;MD6wOFYxQSEQvF2= M2jUZ3NCVkeHUh?=
MFH-ino Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMES3NlQh|ryP NHjzTZRUSU6JRWK=
TGBC24TKB NEDQNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HTTWlEPTB;MD6wOFc3OSEQvF2= Mlf3V2FPT0WU
A388 M3rlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\yTWM2OD1yLkC1NFk2KM7:TR?= MV\TRW5ITVJ?
BB30-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEW0N|ch|ryP MlHaV2FPT0WU
GI-ME-N NGH3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnSYZkUUN3ME2wMlA3OTF6IN88US=> M2PEWnNCVkeHUh?=
TGBC1TKB NHzDfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\UVXRKSzVyPUCuNFYyPjRizszN M2\VS3NCVkeHUh?=
TE-10 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHp[VVKSzVyPUCuNFY{PTdizszN NFPkS5hUSU6JRWK=
A498 NVvwR5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEeyPFQh|ryP M{PW[nNCVkeHUh?=
TE-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFVJY3UUN3ME2wMlA4QDV6IN88US=> M4P6dXNCVkeHUh?=
BB65-RCC MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWzV2ZVUUN3ME2wMlA5OjJ5IN88US=> Mn;lV2FPT0WU
C2BBe1 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fE[mlEPTB;MD6wPFMxQCEQvF2= NHz0S3VUSU6JRWK=
NCI-H747 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEizOlIh|ryP MlvIV2FPT0WU
IST-MES1 NV;aWmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEi1OVIh|ryP NF;t[olUSU6JRWK=
KALS-1 M33mOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfrcXZ6UUN3ME2wMlA6PDlizszN MUXTRW5ITVJ?
GCIY Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nJUmlEPTB;MD6wPVY2PiEQvF2= MXTTRW5ITVJ?
RL95-2 NGTI[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILrZlFKSzVyPUCuNVA{QCEQvF2= M3PzSHNCVkeHUh?=
TE-1 NH;5WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j0OmlEPTB;MD6xNFU1KM7:TR?= M3H2NnNCVkeHUh?=
NCI-H1355 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j3e2lEPTB;MD6xNVAzQCEQvF2= MYTTRW5ITVJ?
SW962 NVTEUlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUGyPVIh|ryP MX7TRW5ITVJ?
KLE M2nY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLjTWM2OD1yLkGxN|E4KM7:TR?= NYHIOFhVW0GQR1XS
MC116 NUTuc3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme4TWM2OD1yLkGxOFEh|ryP NXvrfoNGW0GQR1XS
NMC-G1 NUTES3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjuU4tRUUN3ME2wMlEyPjB4IN88US=> NGnjbWZUSU6JRWK=
KU812 NF;JdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLvTWM2OD1yLkGxPFg{KM7:TR?= NVvneYszW0GQR1XS
COLO-829 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nIeWlEPTB;MD6xNlIyOyEQvF2= MV\TRW5ITVJ?
NTERA-S-cl-D1 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL3TWM2OD1yLkGyNlg{KM7:TR?= MoHEV2FPT0WU
IST-MEL1 NUS4R5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMUO0OUDPxE1? NFPobWNUSU6JRWK=
MLMA Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMUSwN|Ih|ryP NFXRTHNUSU6JRWK=
LS-123 M2DHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\KbmlEPTB;MD6xOFA3PCEQvF2= MnrPV2FPT0WU
LB2518-MEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITMfo9KSzVyPUCuNVQyPjJizszN MYrTRW5ITVJ?
NB69 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFznNJFKSzVyPUCuNVQ1OzZizszN NXHUbI1GW0GQR1XS
8-MG-BA MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMUW0OVgh|ryP NWjrUGJFW0GQR1XS
K5 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvCTWM2OD1yLkG2OFg6KM7:TR?= NGriOWZUSU6JRWK=
KINGS-1 M4HzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnhS5lNUUN3ME2wMlE3PjZ4IN88US=> M4H1OnNCVkeHUh?=
SF268 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHTVmhKSzVyPUCuNVc1ODRizszN M1LQSHNCVkeHUh?=
PF-382 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD1yLkG3Olc5KM7:TR?= M3:xOnNCVkeHUh?=
SH-4 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETwNJlKSzVyPUCuNVg1OTNizszN NGPoTIlUSU6JRWK=
NALM-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLnWZNKSzVyPUCuNVkzQTVizszN NWLUb3lkW0GQR1XS
CP66-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfuXGdKSzVyPUCuNVk2OzFizszN NFe0V5dUSU6JRWK=
697 M4rye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUm5PFch|ryP NY\UXmZPW0GQR1XS
CP67-MEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXkd4J7UUN3ME2wMlIxPDh6IN88US=> MWTTRW5ITVJ?
DSH1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMkSwNFEh|ryP MkW5V2FPT0WU
HCE-4 NWPBNItET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrFXmNIUUN3ME2wMlI3PDN7IN88US=> NH;nSIxUSU6JRWK=
MZ2-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ZfndKSzVyPUCuNlg2OzdizszN NFv2coxUSU6JRWK=
BL-41 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMkmxNlMh|ryP NHjjZmFUSU6JRWK=
HUTU-80 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwM{G0NkDPxE1? MnP2V2FPT0WU
LOXIMVI MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nT[mlEPTB;MD6zNVUxOyEQvF2= Mk\2V2FPT0WU
no-10 NFPPc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHqOXBIUUN3ME2wMlMyQTNzIN88US=> NHfCcVhUSU6JRWK=
KARPAS-422 NH3BNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHpR4pKSzVyPUCuN|M6QTdizszN NHf2cZVUSU6JRWK=
SW684 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofBTWM2OD1yLkO0PVgh|ryP MW\TRW5ITVJ?
SF126 NUC0N5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrUUoNKUUN3ME2wMlM2PDFizszN MUjTRW5ITVJ?
D-263MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HNS2lEPTB;MD6zOlIzPCEQvF2= NGnPdYNUSU6JRWK=
OVCAR-4 NY\jVlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTid5NKSzVyPUCuN|c1OzNizszN MlqwV2FPT0WU
BB49-HNC NXfCSoNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DR[WlEPTB;MD6zPFU6QSEQvF2= NYfoXJJoW0GQR1XS
ONS-76 NGHtfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD1yLkSyPVUyKM7:TR?= Mkn3V2FPT0WU
MZ7-mel MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDSNIJlUUN3ME2wMlQ4QTFzIN88US=> M1P5OnNCVkeHUh?=
RCC10RGB M1rUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\n[GlEPTB;MD60PVEyKM7:TR?= NVTabodLW0GQR1XS
BOKU NVvu[3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHXbJFKSzVyPUCuOFkyOzNizszN NHXGWFBUSU6JRWK=
no-11 M2iweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNUCyNlgh|ryP NEfkfGRUSU6JRWK=
IST-SL2 NX\Ge5JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvibWxyUUN3ME2wMlUxOzB{IN88US=> MmLNV2FPT0WU
RKO NYntcFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnEflhLUUN3ME2wMlUzQTZ4IN88US=> MorWV2FPT0WU
HT-144 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDKTWM2OD1yLkWzOlA6KM7:TR?= NV7jeJNDW0GQR1XS
NCI-H446 NX;rN4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGzcmdKSzVyPUCuOlI4PiEQvF2= Mnz4V2FPT0WU
QIMR-WIL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwN{C2Nlkh|ryP NWj4VGVYW0GQR1XS
MHH-PREB-1 NXTjPJZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwN{S0Olkh|ryP MXzTRW5ITVJ?
EW-16 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XHbGlEPTB;MD63OlE4QCEQvF2= MnXMV2FPT0WU
EW-24 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwN{ixOlUh|ryP MmfMV2FPT0WU
LB373-MEL-D M4HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwOEK1NFgh|ryP Ml7YV2FPT0WU
TE-9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwOEe1N|Ih|ryP Mm\pV2FPT0WU
A3-KAW MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G2W2lEPTB;MD65PFQ2OiEQvF2= MnPHV2FPT0WU
A101D M2m5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn0bFlWUUN3ME2xMlA{ODR|IN88US=> M{nqfnNCVkeHUh?=
OCUB-M NIGwOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMES0NVIh|ryP M4LMfHNCVkeHUh?=
ES4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwMEWxOFUh|ryP MmLhV2FPT0WU
TE-6 NF:yS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHNTWM2OD1zLkKxNlI3KM7:TR?= M1rjfXNCVkeHUh?=
D-502MG M2r3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;UcmlEPTB;MT6yN|M4PiEQvF2= MlWzV2FPT0WU
KNS-42 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjTclZoUUN3ME2xMlI1PDF{IN88US=> MmfVV2FPT0WU
SNU-C2B NFO5[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6SWlEPTB;MT6zNFU5QSEQvF2= MWTTRW5ITVJ?
NCI-H1838 NGjuRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDEfZhKSzVyPUGuN|A4OzNizszN MkfiV2FPT0WU
NKM-1 M3juO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37hTGlEPTB;MT6zNFg2QSEQvF2= MVjTRW5ITVJ?
GI-1 NFL1fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfZe2tMUUN3ME2xMlM3OjJizszN MmD1V2FPT0WU
NB5 NHG1emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2naXmlEPTB;MT6zPVgzPyEQvF2= NVnRZll3W0GQR1XS
CAS-1 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnCUJhKUUN3ME2xMlQxQTl{IN88US=> MYHTRW5ITVJ?
HCE-T NX;CVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Zd2lEPTB;MT61OlcyPCEQvF2= M2nDUnNCVkeHUh?=
SBC-1 NFvXOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PBb2lEPTB;MT61O|k5PCEQvF2= M{\BbHNCVkeHUh?=
JiyoyeP-2003 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HLOmlEPTB;MT63N|Q3PiEQvF2= NIfWc5NUSU6JRWK=
TE-5 M3fCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv6TWM2OD1zLke5NVM6KM7:TR?= NXPhSHgyW0GQR1XS
CAN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvhfnVKSzVyPUGuPFIzPTJizszN NYC5[4tqW0GQR1XS
SK-UT-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC0NphCUUN3ME2yMlE3Pjl|IN88US=> M3LYZ3NCVkeHUh?=
JVM-2 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HvXWlEPTB;Mj6zOlI5PCEQvF2= M{joXnNCVkeHUh?=
LB771-HNC M3\iTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnhTmVKSzVyPUKuOVc2PTFizszN MVXTRW5ITVJ?
NCCIT Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrCTnFKSzVyPUKuPFY3OTZizszN MnTVV2FPT0WU
NCI-H2126 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjIRo1KSzVyPUKuPFc2PTJizszN MlLnV2FPT0WU
Calu-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;LUpRKSzVyPUOuNFU4PDFizszN NYDSOG5WW0GQR1XS
SK-LMS-1 NV2yeXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j0O2lEPTB;Mz6xNVg5PiEQvF2= NXrOdZoxW0GQR1XS
ARH-77 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XtPWlEPTB;Mz60OlkyPSEQvF2= MXnTRW5ITVJ?
NB17 NWXuRY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS3O2lkUUN3ME2zMlY{QDR5IN88US=> NHu5NHhUSU6JRWK=
A253 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkUlRlUUN3ME2zMlc{OjR4IN88US=> M1LnOnNCVkeHUh?=
OPM-2 NH6zSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL1TWM2OD12LkK3Olg2KM7:TR?= M{HUbHNCVkeHUh?=
MV-4-11 NHn5N2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fVbWlEPTB;ND6zOlQ2PCEQvF2= NW\KeWZJW0GQR1XS
SR MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3flUmlEPTB;ND60PVk2PCEQvF2= MXLTRW5ITVJ?
KG-1 NWKzR3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwNkC4OFUh|ryP M2nEZXNCVkeHUh?=
OCI-AML2 NHXadItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwOE[xOVQh|ryP MUDTRW5ITVJ?
D-247MG NIi4dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfKTWFKSzVyPU[uNVI2OTlizszN M2iyRnNCVkeHUh?=
DJM-1 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HzTGlEPTB;Nj60PFU2QCEQvF2= Mn;JV2FPT0WU
RPMI-6666 M3zjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni2TWM2OD15LkK3NFY4KM7:TR?= MWPTRW5ITVJ?
KARPAS-45 NGXQdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vVR2lEPTB;Nz61NVY4OSEQvF2= MU\TRW5ITVJ?
LP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULMTplXUUN3ME23MlU1Pzh{IN88US=> NUTWfI9YW0GQR1XS
RS4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH4[G1uUUN3ME23MlY2Pzh5IN88US=> MlnkV2FPT0WU
DU-4475 M3rkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD4SXU4UUN3ME24MlIyPjV{IN88US=> NFzRRpBUSU6JRWK=
MONO-MAC-6 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorjTWM2OD16LkK3NFY3KM7:TR?= MWfTRW5ITVJ?
NCI-SNU-16 NHjDTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRThwNU[xNlgh|ryP MnX0V2FPT0WU
SJSA-1 NFf6XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz6NIkzUUN3ME24MlczQDB3IN88US=> MkPPV2FPT0WU
MMAC-SF NUTFbplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\kTWM2OD16Lke5N|A4KM7:TR?= NV7qNWJGW0GQR1XS
SK-NEP-1 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorwTWM2OD16Lki5NVU2KM7:TR?= MWfTRW5ITVJ?
J-RT3-T3-5 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwOU[1Nlkh|ryP NUKxZXlvW0GQR1XS
SKM-1 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3OpdpUUN3ME25MlAyPzN2IN88US=> NIrQZ25USU6JRWK=
LB2241-RCC NUDvRYxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fGd2lEPTB;OT6wNlAyOiEQvF2= MlHQV2FPT0WU
SIG-M5 NGXEWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnSdYpiUUN3ME25MlAzPDl|IN88US=> NHzyOZBUSU6JRWK=
EVSA-T NHnmc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzVdWR4UUN3ME25MlI4Pzl|IN88US=> NIKwXZFUSU6JRWK=
GT3TKB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1NWlEPTB;OT6zOVU1PiEQvF2= MojEV2FPT0WU
NB6 M3z5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DlNGlEPTB;OT65NlI2QSEQvF2= NXvSSnhQW0GQR1XS
EHEB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL0OldKSzVyPUGwMlA3PTZizszN M3rKO3NCVkeHUh?=
HEL NVzHbVJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HsSmlEPTB;MUCuOFc4PiEQvF2= NUL0ZZZnW0GQR1XS
ALL-PO NYjEVHJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPyOppKSzVyPUGwMlc6OzhizszN Mki5V2FPT0WU
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P3ZWlEPTB;MUGuNlgzQCEQvF2= M4PTdnNCVkeHUh?=
BC-3 NUTienI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4SWlEPTB;MUKuNVE{QCEQvF2= MXvTRW5ITVJ?
IA-LM NEDoUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonvTWM2OD1zMj60OFQ2KM7:TR?= NHXxTlhUSU6JRWK=
UACC-257 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPl[|RKSzVyPUGyMlkyQThizszN NGS2epVUSU6JRWK=
KP-N-YS M1;2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rKPGlEPTB;MUKuPVI5OyEQvF2= NUW3cFhVW0GQR1XS
Raji NXLDXHBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\CeWlEPTB;MUOuO|Q6PyEQvF2= M4m4UHNCVkeHUh?=
SF539 M3HGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLOpVKSzVyPUGzMlg2PTdizszN NGLGXm5USU6JRWK=
DMS-153 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWWW5sUUN3ME2xOE4xODJ6IN88US=> NYHLSFUxW0GQR1XS
L-540 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF3LkC2O|Ih|ryP Ml7yV2FPT0WU
MN-60 NUHvNodpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXXPJlKSzVyPUG1MlE6PzlizszN MlLKV2FPT0WU
RPMI-8866 NITzNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3uemdYUUN3ME2xO{41PDV2IN88US=> MY\TRW5ITVJ?
NCI-H510A NFPNT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\HZnRKSzVyPUG5MlM6PzNizszN NYrRflg{W0GQR1XS
NB13 NES3R4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7aSYlNUUN3ME2xPU41QDd5IN88US=> MXTTRW5ITVJ?
HAL-01 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnTXFdQUUN3ME2xPU44PTR|IN88US=> M{fmRnNCVkeHUh?=
NCI-H720 NGjsUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrlTWM2OD1{MD6yO|M{KM7:TR?= M13ZTnNCVkeHUh?=
REH NVXyW2JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn2[45RUUN3ME2yNE43OzV5IN88US=> NEnzcWVUSU6JRWK=
KNS-81-FD MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDucoNKSzVyPUKzMlE1PiEQvF2= NEPjVJdUSU6JRWK=
HC-1 M2HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rZWmlEPTB;MkSuOVU2OSEQvF2= MX7TRW5ITVJ?
NCI-H2141 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHuRVE4UUN3ME2yOE44PzV2IN88US=> M4HscXNCVkeHUh?=
MOLT-4 NGjD[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hld2lEPTB;Mk[uOlc2OyEQvF2= NWr1Tod1W0GQR1XS
OMC-1 M173XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ5LkG0NlIh|ryP NInZT3ZUSU6JRWK=
LC-1F NV7iSXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P5V2lEPTB;MkeuN|I1PSEQvF2= NVvQdoYzW0GQR1XS
NCI-H1304 NWrjSIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjEOlVWUUN3ME2yPE4yPjJ6IN88US=> NUHJO2R6W0GQR1XS
BC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1fYhwUUN3ME2yPE43PTFizszN NXTyXY92W0GQR1XS
NCI-H64 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfGTWM2OD1{OT62NlU{KM7:TR?= MVHTRW5ITVJ?
MOLT-16 M{D2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LEbmlEPTB;MkmuOlI6OiEQvF2= M{i4dXNCVkeHUh?=
U-87-MG M2rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrReFZlUUN3ME2zNE44PjZizszN NWHRPHUzW0GQR1XS
GAK NWqxdmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1|MT6yOlg3KM7:TR?= M2TFW3NCVkeHUh?=
ES8 NELqepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PTfGlEPTB;M{KuNVI2OiEQvF2= M1THT3NCVkeHUh?=
HCC1599 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXwTWM2OD1|Mj6zN|I2KM7:TR?= NVHRRYN1W0GQR1XS
EB-3 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN2LkOxNVch|ryP MVfTRW5ITVJ?
HCC1187 NIHP[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3TGlEPTB;M{WuPFA2OiEQvF2= NW\NfJFoW0GQR1XS
SK-PN-DW MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;WfJVKSzVyPUO2MlE6PDNizszN MnPMV2FPT0WU
JVM-3 NHzq[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XU[WlEPTB;M{euNlM{QCEQvF2= NEDTZ3RUSU6JRWK=
HCC2157 NFHTOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j0Z2lEPTB;M{euPVk1PiEQvF2= NHTNfYVUSU6JRWK=
A4-Fuk MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M170WmlEPTB;M{iuNVAxQSEQvF2= NWXu[IZ1W0GQR1XS
COR-L279 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnScJU5UUN3ME20NE4zQDVzIN88US=> MVnTRW5ITVJ?
DEL M1\6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfqRYdKUUN3ME20NU46ODh4IN88US=> NIfXenJUSU6JRWK=
NCI-H1395 NVS1SGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR{LkCxOlMh|ryP NGPqWoNUSU6JRWK=
MHH-NB-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hSmlEPTB;NEOuNFgyQCEQvF2= NWfEO3R6W0GQR1XS
NCI-H2107 NXjPNVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjoTWM2OD12Mz60PFQ3KM7:TR?= NILkR3FUSU6JRWK=
NEC8 M2ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC5NJB4UUN3ME20OE4{OzZizszN M{LFOHNCVkeHUh?=
COLO-684 NX7acJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR4LkKyOVgh|ryP NYHmdWx3W0GQR1XS
LS-411N Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHKSGFKSzVyPUS4MlQ4PDhizszN MoXpV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
稳定性 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID